WALTHAM, Mass. & SAN DIEGO--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced a strategic agreement to commercialize an in vitro diagnostic (IVD) workflow solution for neonatal sequencing, ...

Dipti Mehta has worked as a Senior Application Scientist at Revvity since 2022. Her research in DNA and protein assay development with LabChip GX Touch technology has generated new commercial assays.

Revvity faces multiple headwinds including declining biotech funding, regulatory uncertainty, and reduced academic research budgets. Despite challenges, Revvity's Q1 results beat expectations and the ...

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today announced a collaboration with Eli Lilly and Company (Lilly) that expands access to Lilly’s high-quality predictive models by making ...

Revvity (NYSE:RVTY) is preparing to release its quarterly earnings on Monday, 2026-02-02. Here's a brief overview of what investors should keep in mind before the announcement. Analysts expect Revvity ...

Aaron McDade is a breaking news reporter for Investopedia. He is an experienced journalist who has covered everything from the latest in business and tech news to sports and international news like ...

WALTHAM, Mass.--(BUSINESS WIRE)--#LifeSciences--Revvity, Inc. (NYSE: RVTY) announced the launch of multiple new discovery platforms and technologies at SLAS2026, which are designed to accelerate ...

Life sciences company Revvity (NYSE:RVTY) reported revenue ahead of Wall Streets expectations in Q4 CY2025, with sales up 5.8% year on year to $772.1 million. The company’s full-year revenue guidance ...